Merck Ignores Molnupiravir Cytotoxicity

My article Merck Ignores Molnupiravir’s Cytotoxicity is published in Trial Site News behind paywall. This is a free copy Molnupiravir-Cytotoxic-Merck.PDF.

The fraudulent and malicious marketing of Molnupiravir by Merck explains its campaign against Ivermectin. Its anti-Ivermectin statements should be considered part of its Molnupiravir marketing, and Merck should be held accountable.

From Merck’s statement on Ivermectin:

“KENILWORTH, N.J., Feb. 4, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today affirmed its position regarding use of ivermectin during the COVID-19 pandemic… It is important to note that, to-date, our analysis has identified:

No scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies;
No meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease, and;
A concerning lack of safety data in the majority of studies.”

All three statements are false and known to Merck to be false.

Merck was the original patent or license holder and manufacturer of Ivermectin in the US, so its opinion about Ivermectin has weight. Now the patent has expired, and Ivermectin manufacturing is non-profitable.

Relevant: FDA Guidance for Industry – S2(R1) Genotoxicity Testing